Subscribe to Search results

A letter from Professor Cash to Dr Gunson described the SNBTS management board meeting held on 11 and 12 June 1991 as a "near disaster".

Published on:

Dr Lloyd recorded that "My only regret is that we didn't introduce [HCV testing] earlier. The coordinating activity of the National Directorate appears to have provided us with a lowest common denominator approach rather than a best possible approach."

Published on:

John Canavan wrote for the attention of Baroness Hooper recommending that a "low key announcement" be released to mark the introduction of anti-HCV testing. He noted that "there may...be questions about why testing was not introduced earlier as it was in some other countries."

Published on:

Dr Donald Acheson criticised Peter Jones for going on record regarding suspected infections after using Armour produced Factor 8.

Published on:

Robert Christie produced a document documenting the fallout from Dr Jones' revelations and stated that his view was premature and speculative.

Published on:

A copy of the memo from Dr Peter Harris stated that infected batches of Factorate would be withdrawn due to the announcement that four patients had tested positive for HIV after receiving a batch of Factorate.

Published on:

Dr Jones wrote to Armour to say that, in particular, their product should not be given to "previously untreated seronegative patients" and that he was "particularly averse to its prescription for children."

Published on:

In a meeting with Armour officials, it was decided that unscreened product would not be distributed as long as or unless there were no other product to distribute.

Published on:

In an interoffice memo from Amour, Dr Christie stated that they had a meeting with the DHSS and that there was no evidence that the DHSS regarded Armour products and their current heat treatment method as unsatisfactory and no indication that the DHSS wished for them to withdraw batches of product from unscreened donor pools.

Published on:

At a meeting between the representatives of Rorer Healthcare and the DHSS, the DHSS accepted that the data on viral inactivation presented did look in favour of the heat treatment process. However due to two cases of seroconversion despite heat treatment the DHSS would look carefully to decide if it were necessary to make the company voluntarily withdraw the product.

Published on:

At the meeting between Rorer Healthcare and the DHSS they discussed two cases of seroconversion and discussed if they could hold it from breaking into the public domain for a little longer. They said Dr Hill did not intend to disclose the cases to the haemophilia centre directors unless it was absolutely essential but would have to inform the parents of the children.

Published on:

In a letter from Armour Dr P Harris stated that it should not be overlooked that there may be material in centres or in patients' homes that was not derived from donors tested for anti HTLV-III.

Published on:

In a memo, Dr Harris discussed his conversation with Dr Jones who told him that he did not wish to receive replacement material since it was his belief that their (Armour's) material was less safe in the hepatitis risk area. Dr Jones asked for the letter and this call to be confidential as he had recently had "his wrists slapped for public statements".

Published on:

In a letter to blood banks directors and haemophilia treatment centre coordinators Armour recommended that lots of HT Factorate concentrates derived from non-tested plasma should not be used and that they would arrange for centres to exchange any inventory of product manufactured from untested plasma at no cost to the centres.

Published on:

In response to the media response on AIDS fears prompting recall of blood products Christopher Bishop said that Armour should treat media articles with the contempt they deserved and that they could not make a statement on reviewing the current heat process because they couldn't defend existing treatment and immediately introduce a new one.

Published on:

In a memo Christopher Bishop advised colleagues on responses to be used with regards to queries about them reviewing their heat treatment procedure and said they had a considerable quantity of existing material and they wouldn't want people to hold off ordering until the new product came through.

Published on:

In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat-treated product Robert Christie said Dr Harris had reported the findings in broad outline to the DHSS and promised to supply more information following a written report from Dr Hill. Robert Christie said he agreed that the incident should be reported to the DHSS and a publication describing Dr Hill's experience prepared.

Published on:

In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat treated product Robert Christie said Dr Harris had reported the findings in broad outline to DHSS and promised to supply more information following a written report from Dr Hill

Published on:

Dr Jeffreys Chief Medical Officer said further to the call with Dr Rotblatt they would need to visit the DHSS the next day before the weekend and that Armour would probably be "no doubt looking at voluntarily withdrawing the product on Monday".

Published on:

Armour's Factorate was removed from the market and two of its product licenses relinquished following consultation with the DHSS after two seroconversion cases of AIDS from heat treated Factorate.

Published on: